Key result
Cardiospecific troponins offer critical diagnostic and prognostic value across biological fluids despite unknown metabolic pathways.
Why the study?
Fundamental aspects of the metabolic pathway of cardiospecific troponins, including release mechanisms in non-ischemic extra-cardiac pathologies, circulation, elimination, and transport to other biological fluids, remain definitively unknown.
This review provides a detailed overview of the metabolic pathway of cardiospecific troponins and their diagnostic utility in various clinical scenarios.
Affirms troponins' diagnostic and prognostic value across fluids; leaves open metabolic mechanisms for refined applications.
Many molecules of the human body perform key regulatory functions and are widely used as targets for the development of therapeutic drugs or as specific diagnostic markers. These molecules undergo a significant metabolic pathway, during which they are influenced by a number of factors (biological characteristics, hormones, enzymes, etc.) that can affect molecular metabolism and, as a consequence, the serum concentration or activity of these molecules. Among the most important molecules in the field of cardiology are the molecules of cardiospecific troponins (Tns), which regulate the processes of myocardial contraction/relaxation and are used as markers for the early diagnosis of ischemic necrosis of cardiomyocytes (CMC) in myocardial infarction (MI). The diagnostic value and diagnostic capabilities of cardiospecific Tns have changed significantly after the advent of new (highly sensitive (HS)) detection methods. Thus, early diagnostic algorithms of MI were approved for clinical practice, thanks to which the possibility of rapid diagnosis and determination of optimal tactics for managing patients with MI was opened. Relatively recently, promising directions have also been opened for the use of cardiospecific Tns as prognostic markers both at the early stages of the development of cardiovascular diseases (CVD) (arterial hypertension (AH), heart failure (HF), coronary heart disease (CHD), etc.), and in non-ischemic extra-cardiac pathologies that can negatively affect CMC (for example, sepsis, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), etc.). Recent studies have also shown that cardiospecific Tns are present not only in blood serum, but also in other biological fluids (urine, oral fluid, pericardial fluid, amniotic fluid). Thus, cardiospecific Tns have additional diagnostic capabilities. However, the fundamental aspects of the metabolic pathway of cardiospecific Tns are definitively unknown, in particular, specific mechanisms of release of Tns from CMC in non-ischemic extra-cardiac pathologies, mechanisms of circulation and elimination of Tns from the human body, mechanisms of transport of Tns to other biological fluids and factors that may affect these processes have not been established. In this comprehensive manuscript, all stages of the metabolic pathway are consistently and in detail considered, starting from release from CMC and ending with excretion (removal) from the human body. In addition, the possible diagnostic role of individual stages and mechanisms, influencing factors is analyzed and directions for further research in this area are noted.
No takes yet. Share an insight, caveat, or question.
Aleksey M. Chaulin (2022) conducted a review in Cardiovascular diseases and myocardial infarction. Cardiospecific troponins was evaluated. Cardiospecific troponins serve as critical diagnostic and prognostic markers across various biological fluids, though specific mechanisms of their metabolic pathway remain definitively unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: